FDA review extension keeps Eisai and Biogen waiting on Leqembi Iqlik starting-dose strategy
Alzheimer’s drugs need easier delivery. Eisai and Biogen now face an FDA timing test that could shape Leqembi’s access story.
Pharma & Biotech
Medical Devices & Diagnostics
Why Wenda Pharma’s Phase II data puts BET inhibition back in focus for NUT carcinoma
NUT carcinoma has few options and poor survival. Wenda Pharma’s NHWD-870 may test how fast China can move rare oncology forward.
Pharma & Biotech
Could LANGLARA finally crack the high-cost insulin access problem in the United States?
Insulin access needs more than approvals. LANGLARA’s real test is whether payers and pharmacies turn interchangeability into savings.
Pharma & Biotech
Can China Medical University Hospital, Ever Supreme and SHINE OUT BIO reshape spinal cord injury repair?
New exosome therapy targets spinal cord injury repair non-invasively. Find out how this breakthrough could reshape neuroregenerative medicine.
Pharma & Biotech
Can Uqora’s Target expansion turn urinary health into a mainstream wellness category?
Uqora has entered Target stores and Target.com. Find out what this expansion means for urinary health retail and women’s wellness growth.
Pharma & Biotech
ArkBio pushes AK0406 into first-in-human testing, but can a long-acting flu antiviral carve out real clinical space?
ArkBio has begun Phase I testing of AK0406 in Australia. Read why this long-acting influenza candidate matters and what risks still need proving.
Pharma & Biotech
Why Meiji Seika Pharma is using Singapore to scale its ASEAN vaccine and pharma strategy
Meiji Seika Pharma has launched Meiji Pharma Asia in Singapore. Read what this ASEAN expansion could change for vaccines and regional pharma growth.
Pharma & Biotech
What the NEOK002 IND milestone changes for Biocytogen, NEOK Bio, and ADC competition
NEOK002 has cleared the FDA IND stage. Read why this bispecific ADC matters for solid tumors, clinical strategy, and the next phase of ADC competition.
Pharma & Biotech
Can Ono Pharmaceutical bring clearer treatment sequencing to advanced GIST in Japan?
Ono Pharmaceutical has filed ripretinib in Japan for advanced GIST. Read why the move could reshape late-line treatment access and sequencing.
Pharma & Biotech
How XellSmart’s expanding IND portfolio is shaping the emerging market for CNS cell therapies
XellSmart’s iPSC-derived neuron therapy enters MSA-P trials after FDA and NMPA clearances. Discover what this means for regenerative neurology.